It’s been a busy year for mergers and acquisitions in the Biotechnology and Pharmaceutical industries. Combined spending on M&A is close to $268 billion mid-way through December, with 229 transactions reported. Although the number of deals is 34% lower than 2018’s combined total of 345, spending skyrocketed 62%, from just $165 billion in all of […]
Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
The generic drug segment was hot in 2015, but investor interest has cooled considerably in 2017. Here’s a look at the recent M&A activity.
Fresenius Medical Care has invested more than $5.1 billion in its U.S. pharmaceutical unit, Fresenius Kabi, in April 2017.
Perrigo finally sold its royalty interest in Tysabri, a multiple sclerosis drug that it acquired as part of Elan Corporation back in 2013. Royalty Pharma, the hostile bidder for Elan back then, paid $2.2 billion for Tysabri royalties.
Merck & Co. (NYSE: MRK) added to its product pipeline with the $500 million acquisition Afferent Pharmaceuticals, a privately held biotechnology company in San Mateo, California. Afferent develops therapeutic candidates targeting the P2X3 receptor, for the treatment of common, poorly-managed neurogenic conditions. Afferent’s lead candidate, AF-219, is a selective, non-narcotic, orally administered P2X3 antagonist. It is […]